about
TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in miceThe role of myeloid cells in the promotion of tumour angiogenesisThe pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells.Leucine leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells.Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia.Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications.IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.Period-2: a tumor suppressor gene in breast cancer.Tumor-associated macrophages: effectors of angiogenesis and tumor progression.Immune-mediated mechanisms influencing the efficacy of anticancer therapies.Neutrophils in cancer: neutral no more.Incidence of lymph node metastases in clinical early-stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study.Systemic inflammation: Cancer's long-distance reach to maximize metastasis.Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion.Macrophages and Neutrophils: Regulation of the Inflammatory Microenvironment in Autoimmunity and Cancer.Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.Macrophages promote the progression of premalignant mammary lesions to invasive cancer.Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses.Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions.Generation of a novel mouse model for the inducible depletion of macrophages in vivo.Use of macrophages to target therapeutic adenovirus to human prostate tumors.PyMT-Maclow: A novel, inducible, murine model for determining the role of CD68 positive cells in breast tumor development.CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.Fibrinogen, an endogenous ligand of Toll-like receptor 4, activates monocytes in pre-eclamptic patients.OS006. Functional expression of endogenous ligands of Toll like receptor4 on monocytes and placentae from women during normal pregnancy andpre-eclampsia.Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor.Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.The ERBB network facilitates KRAS-driven lung tumorigenesisInflammation lights the way to metastasisErythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cellsMorphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2⁺ breast cancerRepression of the Type I Interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in Pancreatic Ductal AdenocarcinomaTumour Dormancy and Reawakening: Opportunities and ChallengesLoss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasisTherapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon responseγδ T cells: pleiotropic immune effectors with therapeutic potential in cancerNeutrophil Maturity in Cancer
P50
Q24606406-C9D7FBCB-4938-492C-A22E-50D4245865FAQ29614299-271ABDD2-467C-4BAE-8AA3-1A99B6F3A12DQ30486489-4A326160-93D4-4078-B2AE-0924848B9212Q30490685-7940E9A2-9B01-4EC2-9C0E-B5CC5268A9A1Q33899678-8F7AF612-E791-455F-B671-B1A382A4EDBBQ34091593-095B6128-E002-43DF-9862-3C62E1AB1E12Q35763387-5244CAF3-C356-419B-9F22-4A18C0FAEC47Q36628463-6F43E2B1-12CC-418E-A7E4-E8A4188B4396Q37408808-A9550AA5-AD39-4693-BE95-2815C14EE274Q38413213-A6D85D13-2CB3-424D-98BE-96F4B2FE784AQ38860382-8FC8BD0E-3F70-47F2-8795-F72277A7B5E6Q39176734-3255A15C-E3C8-4D07-9B50-ADA0D6C581E7Q39279591-F51A4C5F-1E29-49A1-AAA7-353B774FBDF8Q39582827-650CD166-67AE-4067-BF0F-A00945B022A9Q41289262-47D44B09-F8F5-43FD-9879-C4A6DCC390D5Q41338881-CA3C3EE6-8E96-4C51-B318-1D2F5D59A475Q41612413-104FF26E-96DF-4CC5-9BD0-4EA99475494DQ42575579-6434406A-61C4-43EF-979D-F75C813A1DFDQ43041612-890AE3FE-5C54-452E-A4BA-2C63E4ECA578Q43814054-FBFE6E09-BBEF-4880-B335-4628F10B48F6Q45866292-8276C110-0982-4C64-83ED-0BE02D9713C4Q47099432-A797F1FF-4288-41DE-BB2F-EAB4BC5F960EQ47141255-D25FFF16-0043-4B71-968E-498C4797A4AEQ50675380-D6198C6B-CC3B-43B8-9A93-3B7A864FD931Q50798720-279244BA-A516-4C20-9A14-D7BED9F2D53CQ50859978-19C6FE09-386F-4E91-96E4-B0389D75D71CQ52431522-C79699F0-9EC8-4F6E-B738-436148E7B55BQ56929860-2FD0C7FE-0CD1-40A3-954B-9063D600FA08Q59092552-3BE253B0-57CC-465D-BC69-59E1A7AE4BC1Q80016174-8D5F6FE7-E0F2-4CEC-8FDA-AECB90822E86Q86860113-FEEA3635-F6B3-4B02-909E-AFDC27539469Q90569268-331EE148-73A2-44E0-B696-BBC5839812FAQ91779659-54BFD431-AC21-4076-83BC-47BDB2B3F4BBQ92322767-843F421F-1997-489F-8EAC-1D993FAEA659Q92461127-E59BB67C-273A-46B8-BEC3-BC49C1B8D4F0Q92826000-2F4EB410-5218-42AC-B69C-162AAA298D4DQ93047686-873970E7-254A-4333-9AED-BAF28874238A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Seth B Coffelt
@es
Seth B. Coffelt
@en
Seth B. Coffelt
@nl
Seth B. Coffelt
@sl
type
label
Seth B Coffelt
@es
Seth B. Coffelt
@en
Seth B. Coffelt
@nl
Seth B. Coffelt
@sl
prefLabel
Seth B Coffelt
@es
Seth B. Coffelt
@en
Seth B. Coffelt
@nl
Seth B. Coffelt
@sl
P106
P1153
16041460400
P21
P2798
P31
P496
0000-0003-2257-2862
P569
2000-01-01T00:00:00Z